TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022
March 08 2022 - 4:30PM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from solid tumors, today announced it will
present a poster at the American Association of Cancer Research
(AACR) Annual Meeting 2022 featuring new preclinical data on an
allogeneic (off-the-shelf) TRuC-T cells, taking place on April
8-13, 2022 in New Orleans, Louisiana. In preclinical studies, this
allogeneic product candidate without an enhancement demonstrated
improved anti-tumor efficacy associated with enhanced persistence
and increased antigen sensitivity in vivo compared to donor-matched
autologous TRuC-T cells targeting mesothelin. Furthermore,
allogeneic TRuC-T cells generated with an additional knockout of
Beta-2-microglobulin (B2M) maintained their potency.
The approach utilized CRISPR/Cas9 endonucleases
to yield fully functional TRuCs with eliminated MHC class 1 surface
expression by B2M gene knockout that lack alloreactivity and
reduced risk of rejection while maintaining signaling properties of
the TCR complex, upregulation of activation markers, secretion of
robust cytokines and lysis of tumor cells in an antigen-specific
manner.
The abstract can be found at www.aacr.org and includes the
following poster presentation details as follows:Title: Engineering
Off-the-Shelf Anti-Mesothelin T Cell Receptor Fusion Construct
(TRuC®) T CellsPoster: 4716Location: Poster Section 36Session
Title: Adoptive Cell Therapy 1Session Date/Time: April
10, 1:30pm - 5:00pm C.S.T.
Following the Company’s presentation at the
medical meeting, the AACR poster presentation will be available on
the Company’s website at www.tcr2.com.
About
TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from solid
tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Forward-looking
Statements
This press release contains forward-looking
statements and information within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. These forward-looking statements include, but are not
limited to, express or implied statements regarding the therapeutic
potential of gavo-cel and TCR2’s other product candidates, timing
for interim updates for the gavo-cel clinical trial, expectations
regarding the timing of TCR2’s TC-510 IND submission and Phase 1
clinical trial initiation, expectations regarding manufacturing
plans and capabilities, future clinical development, partnering and
commercialization plans, the development of the Company’s TRuC-T
cells, their potential characteristics, applications and clinical
utility, and the potential therapeutic applications of the
Company’s TRuC-T cell platform.
The expressed or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation: uncertainties inherent in clinical
studies and in the availability and timing of data from ongoing
clinical studies; whether interim results from a clinical trial
will be predictive of the final results of the trial; whether
results from preclinical studies or earlier clinical studies will
be predictive of the results of future trials; the expected timing
of submissions for regulatory approval or review by governmental
authorities, including review under accelerated approval processes;
orphan drug designation eligibility; regulatory approvals to
conduct trials or to market products; TCR2’s ability to maintain
sufficient manufacturing capabilities to support its research,
development and commercialization efforts, including TCR2’s ability
to secure additional manufacturing facilities; whether TCR2's cash
resources will be sufficient to fund TCR2's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements, the impact of the COVID- 19 pandemic on TCR2’s
ongoing operations; and other risks set forth under the caption
"Risk Factors" in TCR2’s most recent Annual Report on Form 10-K,
most recent Quarterly Report on Form 10-Q and its other filings
with the Securities and Exchange Commission. In light of these
risks, uncertainties and assumptions, the forward-looking events
and circumstances discussed in this press release may not occur and
actual results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. You
should not rely upon forward- looking statements as predictions of
future events. Although TCR2 believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither
TCR2 nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements included in this
press release. Any forward-looking statement included in this press
release speaks only as of the date on which it was made. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor and
Media Contact:Carl MauchSenior
Director, Investor Relations and Corporate Communications (617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024